GLP-1
Glucagon-like peptide-1 is an endogenous incretin hormone. This identity is distinct from prescription GLP-1 receptor agonists, each of which has its own molecular structure, approved regimen, safety evidence, and PK.
Pharmacokinetic model
A route-level PK model for glp-1 is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.
Key facts
- Category
- Endogenous Peptide
- Suggested cadence
- once daily
Research behind this entry
-
GLP-1-based therapies for diabetes, obesity and beyond
Review distinguishes native GLP-1 biology from established and emerging GLP-1-based medicines and discusses their different pharmacokinetic, tolerability, and safety designs. PMID 40281304 is the verified review.
-
Glucagon-Like Peptide-1 Infusion Suppresses Aldosterone Levels in Healthy Normal-Weight Individuals: Double-Blind, Placebo-Controlled Crossover Study.
This citation reports a primary research study involving GLP-1. It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.
2 published studies referenced in the app, each with a plain-language summary.